



TEXAS
Health and Human
Services

**Texas Department of State
Health Services**

Texas Vaccine Providers Webinar

Tuesday, February 22, 2022

Disclaimer

The information presented today is based on CDC's recent guidance and MAY change.

Tuesday, February 22, 2022

Discussion Topics

Opening Remarks – Tony Aragon, MS

COVID-19 Vaccine Updates – Jennifer Moore, BSN, RN

Now You Are Ready to Administer a COVID-19 Vaccine – Jennifer Moore, BSN, RN

Vaccine Safety Systems & Provider FAQs – Merissa Daugherty, BSN, RN

Live Q&A

COVID-19 Vaccine Product Ordering Updates – Oscar Paz

COVID-19 Vaccine ImmTrac2 Reporting – Paul Spock

Live Q&A



Texas Department of State
Health Services

Opening Remarks

Tony Aragon, MS

Director | Immunization Unit

Texas COVID-19 Vaccine Administration Summary

42.22M

Total Doses Administered

17.15M

People fully vaccinated

6.17M

People received a booster dose*

% of Population Fully Vaccinated



≥5 years of age:
64%



≥12 years of age:
69%



≥18 years of age:
70%



≥65 years of age:
84%

% of Population with a Booster Dose*



≥5 years of age:
23%



≥12 years of age:
26%




≥18 years of age:
28%



≥65 years of age:
52%

*The count and percentage of people who received a booster dose includes anyone who is fully vaccinated and has received another dose of COVID-19 vaccine since August 13, 2021. This includes people who received booster doses and people who received additional doses.

7-Day Rolling Average Doses Administered by Dose Number



First doses 7-day Rolling Average includes 1st doses of Moderna, Pfizer, and single doses of Janssen.
Second Doses 7-day Rolling Average includes 2nd doses of Moderna and Pfizer.
Booster/Additional dose is any dose after series completion if dose administered is after 8/13/21.

Data as of 2/18/2022

COVID-19 Vaccine Updates

Jennifer Moore, BSN, RN

Nurse IV – Operations Team | Immunizations Section

New 2022 Immunization Schedules

The new 2022 Immunization Schedules have been released:

2022 Child and Adolescent Schedule:

<https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html>

Child and Adolescent Schedule

Recommended vaccination schedule for ages 18 years or younger

Birth to 18 Years



2022 Adult Schedule:

<https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>

Adult Schedule

Recommended vaccination schedule for ages 19 years or older

19 Years or Older




SAGA Logger

Pfizer vaccine shippers are beginning to transition to an updated data logger from Controlant. This new device called “SAGA Logger” will provide improved performance for monitoring and reporting **during shipment**. The key improvements to this device include:

- Enhanced location accuracy with WiFi
- Utilization of the 4G cellular network
- Interactive LCD display with an improved user interface
- 150 days of backup storage when no cloud is available
- Longer battery life
- Improved data transmission capability

Controlant SAGA Logger



SAGA Logger



The new interactive LCD tracker display shows current temperatures and the minimum and maximum temperatures of the shipper contents during transit. The screen also includes an easy-to-read status indicator for the safer NiMH extended-life battery.

The new SAGA Logger is slightly larger in size and, as with the previous logger, **requires return shipping in the packaging materials provided with your order.**

For additional information or questions, visit the Pfizer Webinar Series for Healthcare Providers presented by the Pfizer. Visit [Pfizer Medical Information](https://www.pfizermedicalinformation.com/en-us/medical-updates) for a complete schedule of trainings for February and March and to access links and passwords for each course.

Now You Are Ready to Administer a COVID-19 Vaccine

Jennifer Moore, BSN, RN

Nurse IV – Operations Team | Immunizations Section

Management of Anaphylaxis at COVID-19 Vaccination Sites

CDC Interim Considerations include guidance on preparing for the potential management of anaphylaxis after COVID-19 vaccination.

- Anaphylaxis, an acute and potentially life-threatening allergic reaction, has been reported rarely following COVID-19 vaccination.
- Under the [Emergency Use Authorizations](#) for COVID-19 vaccines, appropriate medical treatment for severe allergic reactions must be immediately available at any site administering the vaccine in the event that an acute anaphylactic reaction occurs following administration of a COVID-19 vaccine.

Maintaining anaphylaxis medications on hand is a provider responsibility. DSHS does not provide anaphylaxis medications.

COVID-19 EUA: <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>
CDC Management of Anaphylaxis after COVID-19 Vaccination: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html>

The screenshot shows the CDC website interface. At the top, the CDC logo and name are visible. A search bar and a 'Vaccines site' dropdown menu are on the right. Below the header, a green navigation bar contains the text 'Vaccines & Immunizations'. The main content area has a breadcrumb trail: 'CDC > COVID-19 Vaccination > Interim Clinical Considerations'. The title of the page is 'Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination'. Below the title, there is a 'Summary of recent changes (last updated February 11, 2022)' section with a bulleted list of updates. To the right of this summary is a sidebar with two links: 'Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccine Sites [3 pages]' and 'Recognizing and Responding to Anaphylaxis [1 page, 508]'. Below the summary, there is a 'Key Points' section with three bullet points. At the bottom of the main content area is an 'Overview' section with a paragraph of text. On the right side, below the sidebar, is a section titled 'On This Page' with three links: 'Personnel, medications, and supplies for assessing and managing anaphylaxis', 'Routine observation periods following COVID-19 vaccination', and 'Early recognition of anaphylaxis'. At the very bottom of the page, there is a link for 'Management of anaphylaxis at a COVID-19 vaccination location'.

CDC Centers for Disease Control and Prevention
CDC 24/7: Saving Lives. Protecting People™

Search Vaccines site Advanced Search

Vaccines & Immunizations

CDC > COVID-19 Vaccination > Interim Clinical Considerations

Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination

Summary of recent changes (last updated February 11, 2022)

- Added table for potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following COVID-19 vaccination.

Key Points

- Anaphylaxis, an acute and potentially life-threatening allergic reaction, has been reported rarely following COVID-19 vaccination.
- Under the [Emergency Use Authorizations](#) for COVID-19 vaccines, appropriate medical treatment for severe allergic reactions must be immediately available at any site administering the vaccine in the event that an acute anaphylactic reaction occurs following administration of a COVID-19 vaccine.
- These interim considerations provide information on preparing for the initial assessment and potential management of anaphylaxis following COVID-19 vaccination.

Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccine Sites [3 pages]

Recognizing and Responding to Anaphylaxis [1 page, 508]

Overview

Anaphylaxis, an acute and potentially life-threatening allergic reaction, has been reported rarely following COVID-19 vaccination. These interim considerations provide recommendations on assessment and potential management of anaphylaxis following COVID-19 vaccination. Detailed information on CDC recommendations for vaccination, including [contraindications and precautions](#) to vaccination, can be found in the [Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States](#). Patients should be screened prior to receipt of each vaccine dose, and those with a contraindication should not be vaccinated. A [COVID-19 prevaccination questionnaire](#) [6 pages] is available to assist with screening.

On This Page


- Personnel, medications, and supplies for assessing and managing anaphylaxis
- Routine observation periods following COVID-19 vaccination
- Early recognition of anaphylaxis
- Management of anaphylaxis at a COVID-19 vaccination location

Prevaccination Checklist

Providers should ensure patients complete the Prevaccination Checklist for COVID-19 Vaccination to determine whether there is any reason they should not receive the COVID-19 vaccine that day.

If a patient answers “yes” to any question, it does not necessarily mean they should not be vaccinated. It just means additional questions may need to be asked.

Prevaccination Checklist
for COVID-19 Vaccination



For vaccine recipients:
The following questions will help us determine if there is any reason you should not get the COVID-19 vaccine today. **If you answer “yes” to any question, it does not necessarily mean you should not be vaccinated.** It just means additional questions may be asked. If a question is not clear, please ask your healthcare provider to explain it.

Name _____

Age _____

| | Yes | No | Don't know |
|---|--------------------------|--------------------------|--------------------------|
| 1. Are you feeling sick today? | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 2. Have you ever received a dose of COVID-19 vaccine? • If yes, which vaccine product(s) did you receive? <input type="checkbox"/> Pfizer-BioNTech <input type="checkbox"/> Moderna <input type="checkbox"/> Janssen (Johnson & Johnson) <input type="checkbox"/> Another Product _____ • How many doses of COVID-19 vaccine have you received? _____ • Did you bring your vaccination record card or other documentation? | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 3. Do you have a health condition or are you undergoing treatment that makes you moderately or severely immunocompromised? (This would include treatment for cancer or HIV, receipt of organ transplant, immunosuppressive therapy or high-dose corticosteroids, CAR-T-cell therapy, hematopoietic cell transplant [HCT], DiGeorge syndrome or Wiskott-Aldrich syndrome) | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 4. Have you received hematopoietic cell transplant (HCT) or CAR-T-cell therapies since receiving COVID-19 vaccine? | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 5. Have you ever had an allergic reaction to: (This would include a severe allergic reaction [e.g., anaphylaxis] that required treatment with epinephrine or EpiPen® or that caused you to go to the hospital. It would also include an allergic reaction that caused hives, swelling, or respiratory distress, including wheezing.) • A component of a COVID-19 vaccine, including either of the following: ◦ Polyethylene glycol (PEG), which is found in some medications, such as laxatives and preparations for colonoscopy procedures ◦ Polysorbate, which is found in some vaccines, film coated tablets, and intravenous steroids • A previous dose of COVID-19 vaccine | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 6. Have you ever had an allergic reaction to another vaccine (other than COVID-19 vaccine) or an injectable medication? (This would include a severe allergic reaction [e.g., anaphylaxis] that required treatment with epinephrine or EpiPen® or that caused you to go to the hospital. It would also include an allergic reaction that caused hives, swelling, or respiratory distress, including wheezing.) | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| 7. Check all that apply to you: <div><input type="checkbox"/> Am a female between ages 18 and 49 years old <input type="checkbox"/> Am a male between ages 12 and 29 years old <input type="checkbox"/> Have a history of myocarditis or pericarditis <input type="checkbox"/> Have been treated with monoclonal antibodies or convalescent serum to prevent or treat COVID-19 <input type="checkbox"/> Diagnosed with Multisystem Inflammatory Syndrome (MIS-C or MIS-A) after a COVID-19 infection</div> <div><input type="checkbox"/> Have a bleeding disorder <input type="checkbox"/> Take a blood thinner <input type="checkbox"/> Have a history of heparin-induced thrombocytopenia (HIT) <input type="checkbox"/> Am currently pregnant or breastfeeding <input type="checkbox"/> Have received dermal fillers <input type="checkbox"/> Have a history of Guillain-Barré Syndrome (GBS)</div> | | | |

Form reviewed by _____
Adapted with appreciation from the Immunization Action Coalition (IAC) screening checklists
12/02/2021 CS321629E

Date _____

1

Distribute COVID-19 Vaccine Fact Sheet for Recipients and Caregivers

Before an individual receives the COVID-19 vaccine, providers should distribute the Vaccine Information Fact Sheet for Recipients and Caregivers to the individual or their caretaker. The Fact Sheets for Recipients and Caregivers and their translations can be found below:

| | Pfizer COVID-19 Vaccine (Ages 5-11, Orange Cap) | Pfizer COVID-19 Vaccine (Ages 12+, Purple Cap) | Pfizer COVID-19 Vaccine (Ages 12+, Gray Cap) | Moderna COVID-19 Vaccine | Janssen COVID-19 Vaccine |
|--|---|---|---|---|---|
| Vaccine Information Fact Sheet for Recipients and Caregivers | https://www.fda.gov/meda/153717/download | https://www.fda.gov/meda/153716/download | https://www.fda.gov/meda/153716/download | https://www.fda.gov/media/144638/download | https://www.fda.gov/media/146305/download |
| Translations of Fact Sheets for Recipients /Caregivers | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#translated | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#translated | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#translated | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine#translated | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine#translated |

Standing Orders for COVID-19 Vaccines

Review Pfizer's, Moderna's, and Janssen's **Standing Orders for Administering COVID-19 Vaccine** for information on vaccine administration procedure, contraindications and precautions, diluent, dosage, and more.




https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/Pfizer_PED_StandingOrders.pdf



<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/standing-orders.pdf>



<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/gray-cap-Pfizer-BioNTech-standing-orders.pdf>



<https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/downloads/Janssen-Standing-Orders.pdf>

Vaccine Safety Systems & Provider FAQs

Merissa Daugherty, BSN, RN

Nurse III – Operations Team | Immunizations Section

**Get vaccinated.
Get your smartphone.
Get started with v-safe.**



Use your smartphone to tell CDC about any side effects after getting the COVID-19 vaccine. You'll also get reminders if you need a second vaccine dose.

Sign up with your
smartphone's browser at
vsafe.cdc.gov

OR

Aim your smartphone's
camera at this code



Learn more about **v-safe** www.cdc.gov/vsafe



12/01/20

COVID-19 Vaccine Safety Monitoring

v-safe / after vaccination health checker



Clients will need a smartphone to enroll in **v-safe**. It is helpful to have their COVID-19 [vaccination record card](#) to help them remember details about which vaccine they received and when.



V-Safe is [available in multiple languages](#) including English, Spanish, Chinese, Korean, and Vietnamese.



Let your clients know that using v-safe is **quick and easy!** During the first week after each vaccination, **v-safe** sends daily health check-ins that take less than 5 minutes to complete. After that, clients will receive occasional health [check-ins](#).

COVID-19 Vaccine Safety Monitoring

***v-safe** / after vaccination health checker*

Adding a Dependent

Clients can [add any dependent](#) (family member, friend, or individual who relies on them for support) who is vaccinated **in v-safe**. If they already have a **v-safe** account, they can add a dependent to their existing account by following these [instructions](#).



COVID-19 Vaccine Administration Errors Guidance

For all vaccine administration errors:

1. Inform the recipient of the vaccine administration error.
2. Consult with the state immunization program and/ or immunization information system (IIS) to determine how the dose should be entered into the IIS, both as an administered dose and to account for inventory.
3. Providers are required to report all COVID-19 vaccine administration errors—even those not associated with an adverse event—to VAERS (<https://vaers.hhs.gov/>)
4. Determine how the error occurred and implement strategies to prevent it from happening again.

| Interim Revaccination Guidance | | | | | |
|--------------------------------|---|---------------------------|-------------------------|---|----------------------|
| Type | Administration error/deviation | Do <u>NOT</u> repeat dose | Repeat dose immediately | Repeat dose after invalid dose by the minimum interval* | Contact manufacturer |
| Site/route | Incorrect site (i.e., site other than deltoid or anterolateral thigh) | ✓ | | | |
| | Incorrect route (i.e., route other than intramuscular) | ✓ | | | |
| Age | Administered to an unauthorized age group† | ✓ | | | |

<https://www.cdc.gov/vaccines/covid-19/downloads/covid19-vaccine-errors-deviations.pdf>

COVID-19 Vaccine Administration Errors

Review **Appendix A** of the **CDC's Interim Clinical Considerations** for interim recommendations for COVID-19 vaccine administration errors and deviations.

Table. Interim recommendations for COVID-19 vaccine administration errors and deviations

| Type | Administration error/deviation | Interim recommendation |
|------------|--|--|
| Site/route | <ul style="list-style-type: none">Incorrect site (i.e., site other than the deltoid muscle or anterolateral thigh) | <ul style="list-style-type: none">Do not repeat dose. |
| | <ul style="list-style-type: none">Incorrect route (e.g., subcutaneous) | <ul style="list-style-type: none">Do not repeat dose. Inform the recipient of the potential for local and systemic adverse events. |
| Age | <ul style="list-style-type: none">Unauthorized age group (recipients ages 5 years and younger) | <ul style="list-style-type: none">Do not give another dose at this time.* |
| | <ul style="list-style-type: none">Unauthorized age group (recipients ages 5–11 years) | <ul style="list-style-type: none">If Moderna COVID-19 Vaccine administered:<ul style="list-style-type: none">As the first dose, administer a single dose of the age-appropriate Pfizer-BioNTech COVID-19 Vaccine at least 28 days after the Moderna COVID-19 Vaccine dose.As the second dose, or as both the first and second dose, the primary series is complete.If Janssen COVID-19 Vaccine administered:<ul style="list-style-type: none">Because the efficacy of this vaccine in this age group has not been established, administer a single dose of the age-appropriate Pfizer-BioNTech COVID-19 Vaccine at least 28 days after the Janssen COVID-19 Vaccine. |
| | <ul style="list-style-type: none">Unauthorized age group (recipients ages 12–17 years) | <ul style="list-style-type: none">If Moderna COVID-19 Vaccine administered:<ul style="list-style-type: none">As the first dose, administer the age-appropriate Pfizer-BioNTech COVID-19 Vaccine as the second dose at least 28 days after the Moderna vaccine dose. Administer a Pfizer-BioNTech booster dose at least 5 months later.As the second dose, or as both the first and second dose, the primary series is complete. Administer a Pfizer-BioNTech booster |

How to Report an Adverse Event to VAERS

- Go to <https://vaers.hhs.gov/>
- Submit a report online
- For help:
 - Call 1-800-822-7967
 - Email info@VAERS.org
 - Video instructions: <https://youtu.be/sbCWWhcQADFE>
- Please send records to VAERS ASAP if contacted and asked.

Reminder: Providers are not the only individuals who are able to report to VAERS. Patients, parents, and caregivers are also able to do so.



HIPAA permits reporting of protected health information to public health authorities including CDC and FDA

COVID-19 Vaccine FAQ

Providers can reference the **CDC COVID-19 Vaccine FAQs for Healthcare Professionals** to find answers to common questions about vaccination schedule and use, booster doses, indications, contraindications and precautions, storage and handling, administration, documentation, safety, and more.

COVID-19 Vaccine FAQs for Healthcare Professionals

Information for Healthcare Providers, Pharmacists, and Other Vaccine Providers



On This Page

[Vaccination Schedule and Use](#)

[Booster Doses](#)

[Vaccine Indications](#)

[Vaccine Contraindications and Precautions](#)

[Vaccine Storage and Handling](#)

[Vaccine Administration](#)

[Vaccination Documentation](#)

[Vaccine Safety and Efficacy](#)

[Other](#)

Check **vaccine manufacturer websites** for their **vaccine recommendations** for healthcare professionals.

Live Q&A



TEXAS
Health and Human
Services

Texas Department of State
Health Services

COVID-19 Vaccine Product Ordering Updates

Oscar Paz

Program Specialist V | Immunization Unit

Enterprise Portal Access Assistance

Contact Information

Contact VacManagement



Email: COVID19VacMgmt@dshs.Texas.gov



Phone: (833) 832-7068 (Option 2)

If you are a **COVID-19 vaccine provider and a TVFC/ASN provider** experiencing issues logging into the Enterprise Portal or accessing the VAOS App within the portal.

If you are a **COVID-19 vaccine provider and a TVFC/ASN provider** experiencing **single sign-on (SSO) errors**.

If you are an **RE** experiencing issues **logging into VAOS**.



Contact VacShipments



Email: COVID19VacShipments@dshs.Texas.gov



Phone: (833) 832-7068 (Option 2)

If you are a **COVID-19 vaccine provider and a TVFC/ASN provider** and need assistance placing a **vaccine order, reporting waste, confirming shipments, or transferring vaccine** in VAOS.




Pfizer COVID-19 Vaccine Available for Facilities Hosting Vaccination Clinics

DSHS has doses of Pfizer COVID-19 vaccine (purple cap) expiring at the end of March. In order to avoid vaccine waste, DSHS can transfer these doses to facilities hosting mass vaccination clinics.

If your facility is hosting a mass vaccination clinic and needs Pfizer COVID-19 vaccine (purple cap), please contact VacShipments at COVID19VacShipments@dshs.Texas.gov or (833) 832-7068 (Option 2).

Order requests for Pfizer COVID-19 vaccine (purple cap) placed via email or phone will be delivered between **Monday and Wednesday of the week following the request.**




Note: Order requests must be for >500 doses of Pfizer COVID-19 vaccine (purple cap).

Need Help Placing a COVID-19 Vaccine Order?

Assistance for Providers Unable to Access VAOS

If you are a provider who is unable to access VAOS, the VacShipments team can place orders on your behalf.

VacShipments can be contacted by email at COVID19VacShipments@dshs.Texas.gov or by phone at (833) 832-7068 (Option 2).




Updated VAOS Job Aids

Providers are encouraged to review the recently updated step-by-step guides for **placing a COVID-19 vaccine order request, transferring COVID-19 vaccine, and reporting COVID-19 vaccine waste in VAOS.**

These guides can be found on the [COVID-19 Vaccine Management Resources webpage](https://www.dshs.texas.gov/coronavirus/immunize/vaccine-manage-resources.aspx), along with other COVID-19 vaccine provider resources.

COVID-19 Vaccine Management Resources: <https://www.dshs.texas.gov/coronavirus/immunize/vaccine-manage-resources.aspx>
COVID-19 Vaccine Order Request Guide: <https://www.dshs.texas.gov/immunize/covid19/Requesting-COVID-19-Vaccine-Allocations.pdf>
COVID-19 Transfers Guide: <https://www.dshs.texas.gov/immunize/covid19/Transfers-of-COVID-19-Vaccines.pdf>
COVID-19 Reporting Waste Guide: <https://www.dshs.texas.gov/immunize/covid19/Waste-in-VAOS.pdf>



COVID-19 Vaccine ImmTrac2 Reporting

Paul Spock

Training Coordinator – Texas Immunization Registry | Immunization Unit

Reporting Spikevax and Moderna COVID-19 Vaccine

Spikevax™ versus Moderna COVID-19 Vaccine

- On January 31, 2022, the U.S. Food and Drug Administration (FDA) approved a vaccine that has been known as the Moderna COVID-19 Vaccine.
- The approved vaccine will be marketed as Spikevax™ for the prevention of COVID-19 in individuals 18 years of age and older.
- Both have the **same** formulation. Thus, dosage of the vaccine remains the same.
 - Dose 1 & 2 (0.5mL)
 - Dose 3 (0.5 mL) for immunocompromised individuals only
 - Booster dose (0.25 mL)



Texas Department of State
Health Services

Spikevax™ versus Moderna COVID-19 Vaccine

- Providers will phase out the Moderna COVID-19 Vaccine reporting codes as they use up their inventory and switch over to the Spikevax™ reporting code.



Texas Department of State
Health Services

Moderna COVID-19 Vaccine in ImmTrac2

- If you are administering a vaccine labelled "Moderna COVID-19 Vaccine", select that as the trade name in ImmTrac2.

* Date Administered 02/07/2022

Prescribed By

| Remove | Immunization | * Trade Name | * Lot # | Vaccine Eligibility | Prescribed By |
|--------------------------|--------------|--------------------------|---------|---------------------|---------------|
| <input type="checkbox"/> | SARS-COV2 | Moderna COVID-19 Vaccine | ABC123 | | |

* Manufacturer MOD-Moderna US, Inc.

Body Site

Route

Dose Full



Texas Department of State
Health Services

Spikevax in ImmTrac2

- If you are administering a vaccine labelled "Spikevax", select that as the trade name in ImmTrac2.

Enter New Immunization

* Date Administered 02/03/2022

Prescribed By

| Remove | Immunization | * Trade Name | * Lot # | Vaccine Eligibility | Prescribed By |
|--------------------------|--------------|-----------------------|---------|---------------------|---------------|
| <input type="checkbox"/> | SARS-COV2 | Spikevax 100mcg/0.5mL | ABC232 | | |

* Manufacturer MOD-Moderna US, Inc.

Body Site

Route

Dose Full

Reporting via Data Exchange



TEXAS
Health and Human
Services

Texas Department of State
Health Services

Data Exchange Codes for COVID-19 Vaccines

- The NDC and CVX codes used in Data Exchange for COVID-19 vaccines can be found at:

<https://www.cdc.gov/vaccines/programs/iis/COVID-19-related-codes.html>



Texas Department of State
Health Services

Entering Clients From Other Countries




TEXAS
Health and Human
Services

Texas Department of State
Health Services

Entering Clients from Other Countries – Don't Use COVID-19 Rapid Entry


- You CANNOT enter addresses into ImmTrac2 from other countries if you are using the Rapid Entry tool.



Texas Department of State
Health Services

Entering Clients from Other Countries – Works with Regular “Enter New Client”

- You CAN enter addresses into ImmTrac2 that are from other countries using “Enter New Client”.



Texas Department of State
Health Services

Use the Address Information Tab to Enter the Country Name

Address Information ▲

[\[back to top\]](#)

[View Client Address History](#)

Last Updated 02/15/2022

No Viable Address ☐

* Street Address

Other Address

P.O. BOX

Zip +4

* City State


County

Phone Number - -

Extension

E-Mail

Country



Texas Department of State
Health Services

Live Q&A

Texas Vaccine Providers Webinar Survey

We want to hear from you in our Texas Vaccine Providers **Webinar Survey**! This quick survey helps us create content that is relevant and helpful for our Texas providers week over week.

Please complete our post webinar survey for the **2/22 Texas Vaccine Providers Webinar** by Wednesday, 2/23 at 5:00pm CT.

DSHS Texas Providers Webinar Survey - February 22, 2022

What type of organization do you represent?

- ☐ Health Care Provider - Pediatrics
- ☐ Health Care Provider - Dental
- ☐ Health Care Provider - Other
- ☐ Local Health Organization
- ☐ Pharmacy
- ☐ School
- ☐ Correctional Facility
- ☐ Other

Were you able to attend the Texas Provider webinar this week?

- ☐ Yes
- ☐ No
- ☐ Partly

Are there any other topics you would like to see DSHS cover in future webinars? (Select all that apply)

- ☐ Utilizing VAOS
- ☐ Reporting COVID-19 Vaccine Administration into ImmTrac2
- ☐ COVID-19 Vaccine Updates
- ☐ Texas Vaccines for Children (TVFC) Program
- ☐ Adult Safety Net (ASN) Immunization Program
- ☐ Influenza Updates & Guidance
- ☐ Re-enrollment of TVFC/ASN
- ☐ COVID-19 Vaccine Provider Enrollment
- ☐ Other (short answer)

Resources



TEXAS
Health and Human
Services

Texas Department of State
Health Services

Pfizer Medical Affairs-Led Training Events

Goal: Educate providers and immunization staff personnel on the proper use of the Pfizer-BioNTech COVID-19 Vaccine.

Updated Schedule

To access dates and links for upcoming training sessions, please visit:

<https://www.pfizermedicalinformation.com/en-us/medical-updates>

Session topics include:

- Use of each vaccine presentation, including storage, handling, preparation, and administration for:
- Ages 5 through 11 Years: **DILUTE BEFORE USE/Orange Cap**
- Ages 12 Years and Older:
- **DO NOT DILUTE/Gray Cap**
- **DILUTE BEFORE USE/Purple Cap**
- Recent medical updates regarding the vaccine
- An overview of healthcare provider resources
- Question and answer session

| Date & Time | Password |
|--|--------------|
| Attendee link – Tuesday, February 22 - 3pm ET | MMeBHKrM326 |
| Attendee link – Wednesday, February 23 - 12pm ET | NgBarUWa228 |
| Attendee link – Thursday, February 24 - 12pm ET | nMfj6BJEy32 |
| Attendee link – Tuesday, March 1 - 3pm ET | svU8YkF58Qc |
| Attendee link – Wednesday, March 2 - 12pm ET | 3jJ2WJMgeb8 |
| Attendee link – Thursday, March 3 - 12pm ET | 4UBrwQDva77 |
| Attendee link – Tuesday, March 8 - 3pm ET | yMMMMMnf5U44 |
| Attendee link – Wednesday, March 9 - 12pm ET | 2nWpjWa5H8B |

Visit Pfizer's webpage for more information about Pfizer led training events: <https://www.pfizermedicalinformation.com/en-us/medical-updates>

COVID-19 Vaccine Product Availability

When you enter the “doses requested,” remember that each COVID-19 vaccine type ships in different pack sizes. Use the table below to determine how many doses to request:

| Moderna | | Pfizer Adult/Adolescent (12+ yrs) | | Pfizer Pediatric (5 -11 yrs) | | Janssen/J&J |
|---|---|---|---|--|---|---|
| <100 Doses | >100 Doses | <300 Doses | >300 Doses | <100 Doses | >100 Doses | >100 Doses |
| Place orders in multiples of 10 doses (1 vial) up to a maximum of 60 doses | Place orders in multiples of 100 doses | Place orders in multiples of 6 doses (1 vial) up to a maximum of 102 doses | Place orders in multiples of 300 doses | Place orders in multiples of 10 doses (1 vial) up to a maximum of 100 doses | Place orders in multiples of 100 doses | Place orders in multiples of 100 doses |

Note! As of 10/15/2021, providers placing order requests for more than one COVID-19 vaccine presentation in VAOS will be required to place a *separate order request* for each COVID-19 vaccine presentation they wish to order.

COVID-19 Vaccine Provider Support

Call the COVID-19 Provider Support Help Desk at 833-832-7068

Hours of Operation: Monday to Friday, 8 a.m. - 5 p.m. CT

| Category | COVID-19 Vaccine Provider Enrollment (Syntropi) | COVID-19 Vaccine Provider Information and Safety Reporting | Vaccine Allocation & Ordering System (VAOS) | Vaccine Distribution & Shipments | Reporting for COVID-19 Vaccines |
|--------------------------|--|---|--|---|--|
| Sample questions | <ul style="list-style-type: none"> How to become a COVID-19 Vaccine Provider In-progress applications Update Enrollment accounts, including population numbers, email addresses, or primary/backup coordinators | <ul style="list-style-type: none"> COVID-19 vaccine safety & medical info Administration of vaccine Reporting adverse events to VAERS Questions/concerns for clinical vaccine considerations | <ul style="list-style-type: none"> Access to VAOS Question about completing a task or process in VAOS or dashboards Provider Webinars | <ul style="list-style-type: none"> Tracking shipments Orders Vaccine transfer Waste disposal Changing inventory in VAOS | <ul style="list-style-type: none"> Reporting to ImmTrac2 via online web application |
| Provider Support Channel | Provider Help Desk: (833) 832-7068 (Option 1) or (877) 835-7750 or Email: COVID19VacEnroll@dshs.texas.gov HealthCare Providers/Professionals https://www.cdc.gov/vaccines/hcp/index.html | COVID-19 Nurse Call Center: (833) 832-7068 (Option 4) or Texas 2-1-1 (Option 6), 8 a.m. to 5 p.m., Monday through Friday or Email: CoronaVirus@dshs.texas.gov General Immunization Questions: COVIDvaccineQs@dshs.texas.gov | Covid-19 Vaccine Management: (833) 832-7068 (Option 2) or Email: COVID19VacMgmt@dshs.texas.gov | Vaccine Shipments: (833) 832-7068 (Option 2) or Email: COVID19VacShipments@dshs.texas.gov For questions about COVID-19 vaccine storage/handling, refer to the manufacturer resources . | ImmTrac2 team: (833) 832-7068 (Option 3) or (800) 348-9158, 8 a.m. to 4:30 p.m., Monday through Friday or Email: ImmTrac2@dshs.texas.gov ImmTracMU for Data Exchange: 800-348-9158 or Email: ImmTracMU@dshs.texas.gov |
| Include in email: | Current and new vaccine coordinator name and email address (if new coordinators requested) | | Provider name, org code, and primary and backup vaccine coordinator names and email addresses | Provider name, org code, and service request number or shipment number | |

Identification, Disposal, and Reporting of COVID-19 Vaccine Waste

The Operational Summary for the identification, disposal, and reporting of waste has been developed into a webpage for jurisdictions and providers. This page provides information to help awardees and immunization managers identify, handle, dispose of, and report waste in **COVID-19 vaccination programs**. This waste management guidance should not be used for non-COVID-19 vaccines, which are covered under other Centers for Disease Control and Prevention (CDC) vaccination programs. The webpage can be found at the link below:

<https://www.cdc.gov/vaccines/covid-19/hcp/wastage-operational-summary.html>

COVID-19 Vaccine Waste Guidance

Waste Disposal and Reporting Resources

While it is important to try to use every dose of vaccine possible, that should not be at the expense of missing an opportunity to vaccinate every eligible person when they are ready to get vaccinated.

The Texas Commission on Environmental Quality provides guidance on waste disposal:
<https://www.tceq.texas.gov/response/covid-19/waste-disposal-guidance>



For guidance on reporting Moderna doses wasted, see the following guide:
<https://www.dshs.texas.gov/immunize/covid19/Moderna-Wastage-Table-Texas.pdf>



For guidance on reporting waste in VAOS, see the following guide:
<https://www.dshs.texas.gov/immunize/covid19/Waste-in-VAOS.pdf>

COVID-19 Vaccine Waste
Reporting Waste and Generating Waste Reports in VAOS
October 25, 2021

For questions about reporting waste, call (833) 832-7068 (Option 2) or email COVID19VacShipments@dshs.Texas.gov.

Updated COVID-19 Vaccine Web Resources

The following CDC webpages have been updated:

- [Understanding mRNA COVID-19 Vaccines](#)
- [About COVID-19 Vaccine Delivered and Administration Data](#)
- [Reporting County-Level COVID-19 Vaccination Data](#)
- [COVID-19 Vaccines for Moderately or Severely Immunocompromised People](#)
- [Benefits of Getting a COVID-19 Vaccine](#)

Billing Codes

For questions related to billing, visit the Centers for Medicare and Medicaid Services (CMS) resource, which includes CPT codes for COVID-19 vaccines.

CMS COVID-19 Vaccines and Monoclonal Antibodies:
<https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies>

The screenshot shows the CMS.gov website. The header includes the CMS.gov logo, a search bar, and navigation links for Medicare, Medicaid/CHIP, Medicare-Medicaid Coordination, Private Insurance, Innovation Center, Regulations & Guidance, Research, Statistics, Data & Systems, and Outreach & Education. The breadcrumb trail reads: Home > Medicare > Medicare Part B Drug Average Sales Price > COVID-19 Vaccines and Monoclonal Antibodies. The left sidebar lists links for Medicare Part B Drug Average Sales Price from 2022 to 2005, Medicare Part B Drugs Regulations, and COVID-19 Vaccines and Monoclonal Antibodies. The main content area is titled "COVID-19 Vaccines and Monoclonal Antibodies" and contains text about Medicare Part B payment for COVID-19 vaccines and certain monoclonal antibodies during the Public Health Emergency. It mentions that CMS has released a set of toolkits for providers, states, and insurers to help with reimbursement. Below the text is a table titled "Payment Allowances and Effective Dates for COVID-19 Vaccines and their Administration During the Public Health Emergency:(DOS = Date of Service, TBD = To Be Determined)".

| CPT Code or HCPCS Code | CPT or HCPCS Short Descriptor | Labeler Name | Vaccine/Procedure Name | National Payment Allowance Effective for Claims with DOS on or after 03/15/2021 | National Payment Allowance Effective for Claims with DOS through 03/14/2021 | Effective Dates |
|------------------------|-------------------------------|--------------|--|---|---|------------------|
| 91300 | SARSCOV2 VAC 30MCG/0.3ML IM | Pfizer | Pfizer-BioNTech Covid-19 Vaccine | \$0.010 ^[1] | \$0.010 ^[1] | 12/11/2020 – TBD |
| 0001A | ADM SARSCOV2 30MCG/0.3ML 1ST | Pfizer | Pfizer-BioNTech Covid-19 Vaccine Administration – First Dose | \$40.000 ^[2] | \$16.940 ^[2] | 12/11/2020 – TBD |

Ordering COVID-19 Vaccination Record Cards

COVID-19 Vaccine Providers can order additional vaccination record cards.

To order the COVID-19 vaccination record cards, email the following information in the format listed to the COVID-19 Vaccine Provider Help Desk at COVID19VacEnroll@dshs.texas.gov. Please note, ***providers may not exceed 50 cards per request*** and quantities ordered will be tracked by DSHS.

- *Quantity Requested*
- PIN:
- Name of facility:
- Point of contact name:
- Address line 1:
- Address line 2:
- City, State, Zip code:

For more information, refer to the email sent from DSHS via GovDelivery on 7/19/2021.

COVID-19 VAOS Job Aids

In the [COVID-19 VAOS Job Aid Catalog](#) you can find all the DSHS job aids you may need as a COVID-19 vaccine provider.

Vaccine Allocation & Order System (VAOS) – Learning Resources

COVID-19 Vaccine Job Aids

- [VAOS Tips & Tricks](#) (11/2/2021)
- [COVID-19 Vaccine Data Dashboard](#) (6/29/2021)
- [COVID-19 Vaccine Product Availability](#) (10/28/2021)
- [COVID-19 Vaccine Order Requests in VAOS](#) (10/25/2021)
- [Vaccine Transfers in VAOS](#) (10/25/2021)
- [VAOS Quick Start Guide](#) (11/19/2021)
- [COVID-19 Vaccine Shipments](#) (10/25/2021)
- [Reporting Waste in VAOS](#) (10/25/2021)
- [Moderna Wastage Table](#) (11/2/2021)
- [Generating Reports in VAOS](#) (6/18/2021)

COVID-19 Therapeutics Job Aids

- [COVID-19 Therapeutics Job Aid](#) (9/24/2021)
- [Therapeutics Enrollment Guide](#) (11/10/2021)

VAOS E-Learnings

- [COVID-19 Vaccine & Therapeutics VAOS Videos](#)
- [TVFC/ASN VAOS Videos](#)

TVFC/ASN Job Aids

- [VAOS Quick Start Guide](#) (11/19/2021)
- [Open Ordering](#) (10/20/2021)
- [Uploading Temperature Logs](#) (10/18/2021)
- [Vaccine Shipments](#) (10/18/2021)
- [Vaccine Transfers](#) (10/18/2021)
- [Entering Doses Administered](#) (10/18/2021)
- [Reconciling Physical Inventory](#) (10/18/2021)
- [Reporting Waste](#) (10/18/2021)
- [Generating Reports](#) (10/18/2021)

Updated 11/10/2021

COVID-19 Vaccine Fact Sheets

| | Pfizer COVID-19 Vaccine (Ages 5-11, Orange Cap) | Pfizer COVID-19 Vaccine (Ages 12+, Purple Cap) | Pfizer COVID-19 Vaccine (Ages 12+, Gray Cap) | Moderna/Spikevax COVID-19 Vaccine | Janssen COVID-19 Vaccine |
|--|---|---|---|---|---|
| Fact Sheet for Healthcare Providers | https://www.fda.gov/media/153714/download | https://www.fda.gov/media/153713/download | https://www.fda.gov/media/153715/download | https://www.fda.gov/media/144637/download | https://www.fda.gov/media/146304/download |
| Vaccine Information Fact Sheet for Recipients and Caregivers | https://www.fda.gov/media/153717/download | https://www.fda.gov/media/153716/download | https://www.fda.gov/media/153716/download | https://www.fda.gov/media/144638/download | https://www.fda.gov/media/146305/download |
| Translations of Fact Sheets for Recipients and Caregivers | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#translated | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#translated | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#translated | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine#translated | https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine#translated |
| Other | | | | Important Prescribing Information: https://www.fda.gov/media/153354/download Spikevax package insert: https://www.fda.gov/media/155675/download | |

Vaccine Manufacturer Resources



Medical Information

Phone: 800-438-1985

Email:

PfizerMedicalInformation@pfizer.com

Website: www.PfizerMedInfo.com



Medical Information

Phone: 866-663-3762

Email: MedInfo@modernatx.com

Temperature excursion related questions:

Email: excursions@modernatx.com



Medical Information

Phone: 800-565-4008

Temperature excursion related questions:

Email:

JSCCOVIDTEMPEXCURSION@its.jnj.com

Disclaimer

The information presented today is based on CDC's recent guidance and MAY change.

Tuesday, February 22, 2022

Thank you!